647

Pfizer Inc (PFE-N)

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical

Pfizer Inc
PFE-N

80 watching

Join the Discussion

Expert Opinions
0 comments
Your Reaction

0 0 0 0 0

What the experts are saying about PFE-N

Signal	Opinion	Expert
WEAK BUY	Pfizer Inc(PFE-N) March 25, 2019 Healthcare in general has outperformed in every bear market. A lot of it comes from large cap pharma companies. He prefers LLY-N. But there is no question that this one is interesting and has good management. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Healthcare in general has outperformed in every bear market. A lot of it comes from large cap pharma companies. He prefers LLY-N. But there is no question that this one is interesting and has good management. biotechnology/pharmaceutical 0 0 0 0 0 0 comments David Fingold VP and Por, Dynamic Funds... Price $41.890 Owned No

COMMENT	Pfizer Inc(PFE-N) March 21, 2019 It is a safe dividend play. He looks at total return so dividends are important but recommends you don’t get caught in a dividend trap where there is capital at risk. A lot of dividend payers have moved their valuations to historical high levels. You have to be careful. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	It is a safe dividend play. He looks at total return so dividends are important but recommends you don’t get caught in a dividend trap where there is capital at risk. A lot of dividend payers have moved their valuations to historical high levels. You have to be careful. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Gordon Reid President, GoodReid Investment ... Price $42.350 Owned Unknown
TOP PICK	Pfizer Inc(PFE-N) March 11, 2019 He likes this group and PFE is one of the few that has tested support lines. This has big potential to return to the mid/high-$40s soon. He likes it here. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	He likes this group and PFE is one of the few that has tested support lines. This has big potential to return to the mid/high-$40s soon. He likes it here. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Elliott Fishman Director o, Trading Services Gro... Price $41.500 Owned No
BUY	Pfizer Inc(PFE-N) February 22, 2019 Great long base from 2015-18. The greater the base, the better the case. It broke out in mid-2018 and pulled back a bit. It looks healthy though. The chart looks encouraging. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Great long base from 2015-18. The greater the base, the better the case. It broke out in mid-2018 and pulled back a bit. It looks healthy though. The chart looks encouraging. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Keith Richards Portfolio , ValueTrend Wealth Ma... Price $42.960 Owned Unknown
TOP PICK	Pfizer Inc(PFE-N) February 8, 2019 He sees about 18% upside and likes the healthcare sector. Yield 3.43% (Analysts’ price target is $45.85) biotechnology/pharmaceutical 0 0 0 0 0 0 comments	He sees about 18% upside and likes the healthcare sector. Yield 3.43% (Analysts’ price target is $45.85) biotechnology/pharmaceutical 0 0 0 0 0 0 comments Brian Acker, CA Chief Exec, Acker Finley Inc.... Price $42.095 Owned Yes
DON'T BUY	Pfizer Inc(PFE-N) February 6, 2019 Merck vs. Pfizer Two large pharma companies that are treading water. A lot of the drugs they develop are coming off patent. You must look at their pipelines, with Merck doing very well while Pfizer has some good franchises, like Lipitor. Merck likely has the better pipeline. Neither has enough revenue growth or cash flow to entice him to buy. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Merck vs. Pfizer Two large pharma companies that are treading water. A lot of the drugs they develop are coming off patent. You must look at their pipelines, with Merck doing very well while Pfizer has some good franchises, like Lipitor. Merck likely has the better pipeline. Neither has enough revenue growth or cash flow to entice him to buy. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Gordon Reid President, GoodReid Investment ... Price $42.330 Owned No
PAST TOP PICK	Pfizer Inc(PFE-N) January 31, 2019 (A Top Pick Jan 10/18, Up 21%) This was the conservative pick. He thought it was oversold and it had a nice run back to where it is. He trimmed a little back and is not as positive on it now. They are going to pool their consumer product divisions with Glaxo. Probably 5-10% return this year. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	(A Top Pick Jan 10/18, Up 21%) This was the conservative pick. He thought it was oversold and it had a nice run back to where it is. He trimmed a little back and is not as positive on it now. They are going to pool their consumer product divisions with Glaxo. Probably 5-10% return this year. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Robert Lauzon Deputy Chi, Middlefield Capital ... Price $42.450 Owned Yes
DON'T BUY	Pfizer Inc(PFE-N) December 19, 2018 They make their money by constantly cost cutting. When their drugs go off-patent then they need to find another to replace it. It is a leaky-boat story. When you look at the cost multiples, which he thinks are expensive, he would pass on this. He would consider bio-pharma instead. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	They make their money by constantly cost cutting. When their drugs go off-patent then they need to find another to replace it. It is a leaky-boat story. When you look at the cost multiples, which he thinks are expensive, he would pass on this. He would consider bio-pharma instead. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Gordon Reid President, GoodReid Investment ... Price $41.970 Owned No
BUY	Pfizer Inc(PFE-N) December 11, 2018 2019 outlook? The US healthcare sector has been very defensive in this market; they're not as off other sectors. The sector went sideways during the 2016 US election campaign. PFE has announced the price of 40-50 of their drugs will be raised. Plenty of runway in this company. But in 2019, if there's a market recovery, money will flow out of healthcare and back into tech. But you're good to own this. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	2019 outlook? The US healthcare sector has been very defensive in this market; they're not as off other sectors. The sector went sideways during the 2016 US election campaign. PFE has announced the price of 40-50 of their drugs will be raised. Plenty of runway in this company. But in 2019, if there's a market recovery, money will flow out of healthcare and back into tech. But you're good to own this. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Mike S. Newton, Director &, Scotia Wealth Manage... Price $44.010 Owned Unknown
TOP PICK	Pfizer Inc(PFE-N) December 6, 2018 A defensive name. Revenues at $52 billion per year. ROE is going higher. Dividend yield is 3.0% and P/E is 15. Strong pipeline. (Analysts’ price target is $45.09) biotechnology/pharmaceutical 0 0 0 0 0 0 comments	A defensive name. Revenues at $52 billion per year. ROE is going higher. Dividend yield is 3.0% and P/E is 15. Strong pipeline. (Analysts’ price target is $45.09) biotechnology/pharmaceutical 0 0 0 0 0 0 comments Stan Wong Director &, Private Wealth Manag... Price $44.980 Owned Unknown
HOLD	Pfizer Inc(PFE-N) December 3, 2018 Likes it. Diversified pharma. Good pipeline of assets that look robust. Trades at 15x earnings, which is reasonable. Slightly lower growth rate than peers but pays a good dividend. The chart looks fantastic and has benefited from the recent safety trade. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Likes it. Diversified pharma. Good pipeline of assets that look robust. Trades at 15x earnings, which is reasonable. Slightly lower growth rate than peers but pays a good dividend. The chart looks fantastic and has benefited from the recent safety trade. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Paul Macdonald Chief Inve, Harvest Portfolios G... Price $45.990 Owned Yes
PAST TOP PICK	Pfizer Inc(PFE-N) November 22, 2018 (A Top Pick Jan 10/18, Up 22%) Often last year's losers are this year's winners. This one he warmed up to when it had a good set-up. It is one of his main holdings in the healthcare space. They are becoming more innovative. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	(A Top Pick Jan 10/18, Up 22%) Often last year's losers are this year's winners. This one he warmed up to when it had a good set-up. It is one of his main holdings in the healthcare space. They are becoming more innovative. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Robert Lauzon Deputy Chi, Middlefield Capital ... Price $0.000 Owned Yes
DON'T BUY	Pfizer Inc(PFE-N) October 29, 2018 A very defensive stock with great products and brand, but little earnings growth, not enough for him. Pays a good dividend yield and the company won't go out of business. It will weather this downturn. He prefers Gilead. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	A very defensive stock with great products and brand, but little earnings growth, not enough for him. Pays a good dividend yield and the company won't go out of business. It will weather this downturn. He prefers Gilead. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Don Lato President, Padlock Investment M... Price $43.230 Owned No
HOLD	Pfizer Inc(PFE-N) August 23, 2018 Very much a value stock. Not a lot of growth. You can’t too far wrong at these levels. He likes a little more growth. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Very much a value stock. Not a lot of growth. You can’t too far wrong at these levels. He likes a little more growth. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Don Lato President, Padlock Investment M... Price $42.200 Owned No
DON'T BUY	Pfizer Inc(PFE-N) August 7, 2018 Not a big owner of pharmaceuticals, because they’re under pricing pressure. Pfizer’s thinking of selling off consumer division. It’s OK, but the medical device sector’s doing better than pharma. Whole sector’s not performing well. Only pharma he owns is Novo Nordisk. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Not a big owner of pharmaceuticals, because they’re under pricing pressure. Pfizer’s thinking of selling off consumer division. It’s OK, but the medical device sector’s doing better than pharma. Whole sector’s not performing well. Only pharma he owns is Novo Nordisk. biotechnology/pharmaceutical 0 0 0 0 0 0 comments David Driscoll President , Liberty Internationa... Price $40.840 Owned No

4+

JOIN THE DISCUSSION
4 comments in the last 7 days

Stockchase, in its reporting on what has been discussed by indviduals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc. & Wealthica Financial Technology Inc.